A Randomized, 18-Week, Placebo-Controlled, Double-Blind, Parallel-Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) in Subjects with Mild to Moderate AD with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil

Study Status: 
Study Description: 

The purpose of this clinical trial is to evaluate the safety of PF-05212377 (SAM-760) and the effect of PF-05212377 (SAM-760) on cognition and some behavioral symptoms associated with Alzheimer's disease.


We are looking for participants who:


-- have a diagnosis of Alzheimer's disease

-- are age 60 or older

-- have a reliable caregiver or family member who is able to accompany them to study visits

-- are in stable medical condition

-- are on stable doses of Aricept (donepezil)

-- are not on any other medications for Alzheimer's disease (antidepressants are allowed)


More information is attached.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

RecruitmentDocument (5).pdf45.14 KB